is a topic covered in the Davis's Drug Guide
To view the entire topic, please sign in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
anti-multiple sclerosis agents
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Quiring, Courtney, et al. "Ocrelizumab." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110474/all/ocrelizumab.
Quiring C, Sanoski CA, Vallerand AH. Ocrelizumab. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110474/all/ocrelizumab. Accessed October 22, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Ocrelizumab. In Davis's Drug Guide. Available from https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110474/all/ocrelizumab
Quiring C, Sanoski CA, Vallerand AH. Ocrelizumab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 October 22]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110474/all/ocrelizumab.
TY - ELEC
T1 - ocrelizumab
ID - 110474
A1 - Quiring,Courtney,
AU - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110474/all/ocrelizumab
PB - F.A. Davis Company
ET - 16
DB - Pediatrics Central
DP - Unbound Medicine